Form 4: Imunon Director Pellizzari Acquires Stock Options

Christine A. Pellizzari, a director of Imunon, Inc., acquired stock options exercisable for 4,500 shares of common stock at a price of $0.86 on March 15, 2024.

Summary

• On March 15, 2024, Christine A. Pellizzari, a director of Imunon, Inc., acquired stock options.
• The options are exercisable for 4,500 shares of Imunon's common stock.
• The exercise price of the options is $0.86 per share.
• The options vest in three tranches: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.
• Following the transaction, Pellizzari directly owns 14,166 shares of Imunon common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider transactions.

Positives

• A director's acquisition of stock options can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the director.

Key Dates

Keywords

Imunon, Director, Stock Options, Beneficial Ownership, Form 4, Pellizzari, IMNN